Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gross Profit | $16.2B | $18.6B | $20.9B | $23.6B | $25.0B | $27.0B | $26.9B | $27.6B | $22.6B | $20.5B | $20.3B | $20.1B | $18.9B | $18.1B | $17.2B | $19.5B | $21.3B | $25.0B | $32.0B | $37.8B |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, AstraZeneca PLC's last 12-month Gross Profit is $41.4B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, AstraZeneca PLC's Gross Profit growth was 14.6%. The average annual Gross Profit growth rates for AstraZeneca PLC have been 23.8% over the past three years, 16.9% over the past five years.
Over the last year, AstraZeneca PLC's Gross Profit growth was 14.6%, which is higher than industry growth of 0.3%. It indicates that AstraZeneca PLC's Gross Profit growth is Good.